The Smads are the signaling mediators of the TGFb superfamily. In the present study, we examined Smad expression in mouse epidermis and chemically-induced skin tumors. Mutations in Smad2 and -4 genes were also screened. Transcripts of Smad1 through -5 were constantly expressed in the epidermis regardless of changes in TGFb signaling, state of dierentiation and stages of carcinogenesis. Smad7 transcripts were barely detectable in keratinocytes, but were induced by TGFb1 treatment and in chemically-induced skin tumors. At the protein level, Smad1 was detected throughout the epidermis, whereas Smad2 through -5 exhibited greater levels in suprabasal layers than basal keratinocytes. In cultured keratinocytes, Smad2, -3 and -4 underwent nuclear translocation upon TGFb1 treatment. Furthermore, nuclear translocation of Smads correlated with decreased BrdU labeling in proliferative keratinocytes. Although no mutations were detected in the Smad2 and -4 genes in tumors, proteins of Smad1 through -5 were partially or completely lost in carcinomas. These data document that Smads are expressed at high levels in the epidermis and mediate signaling of the TGFb superfamily. During skin carcinogenesis, loss of Smad1 through -5 and overexpression of Smad7 may contribute to the loss of growth inhibition mediated by TGFb superfamily members, thus resulting in tumor progression. Oncogene (2001) 20, 471 ± 483.
Introduction
The transforming growth factor b (TGFb) superfamily is a multi-functional cytokine family that regulates cell growth, tissue remodeling and angiogenesis (for reviews, see Sporn, 1987, 1993) , Recently, Smad family members (vertebrate homologs of mothers against decapentaplegic in Drosophila and sma in C. elegans) have been identi®ed as major intracellular mediators of TGFb signaling (for reviews, see Kawabata and Miyazono, 1999) . They are divided into three groups: Receptor-speci®c Smads (R-Smad), a generic Smad (Co-Smad), and anti-Smads. Initial characterization of R-Smads showed that Smad1 and -5 mediate bone morphogenetic protein (BMP) signaling, and Smad2 and -3 mediate TGFb and activin signaling (Goto et al., 1998; Liu et al., 1997; Souchelnytskyi et al., 1997) . Increasing evidence suggests that signaling mediated by R-Smads is more complicated than initially depicted. For instance, Smad5 has also been suggested to mediate TGFb signaling (Chang et al., 1999) . Furthermore, R-Smads may mediate additional signal transduction pathways which are independent of the TGFb superfamily (Kretzschmar and Doody, 1997; Kretzschmar et al., 1999) . Smad4 is a Co-Smad, which forms a heteromeric complex with one of the R-Smads. Upon ligand binding of the receptors, the R-Smads are phosphorylated by the type I receptors of the TGFb superfamily and subsequently form heteromeric complexes with Smad4 and translocate from the cytoplasm to the nucleus. The Smad complex in the nucleus functions as a transcription factor. The anti-Smads, Smad6 and -7, block Smad signaling by inhibition of R-Smad phosphorylation and subsequent nuclear translocation (Imamura et al., 1997; Nakao et al., 1997) .
TGFb signaling plays a pivotal role in maintenance of skin homeostasis. Transgenic mice overexpressing the TGFb1 ligand exhibited a severe growth arrest in the epidermis (Sellheyer et al., 1993; Wang et al., 1999) , which resulted in neonatal lethality in one instance (Sellheyer et al., 1993) . In contrast, transgenic mice overexpressing a dominant negative type II TGFb receptor (DbRII) exhibited epidermal hyperproliferation (Wang et al., 1997) . Overexpression of other TGFb superfamily members, e.g., BMP4 or BMP6, in transgenic mouse epidermis, also caused abnormalities in hair and epidermal growth (Blessing et al., 1993 (Blessing et al., , 1996 . In addition, alterations in TGFb signaling pathway contribute greatly to skin carcinogenesis. For instance, overexpression of TGFb1 inhibits tumor development at early stages, but accelerates tumor progression at later stages (Cui et al., 1996) ; whereas loss of TGFb1 expression results in early progression to malignancy (Glick et al., 1994) . Transgenic mice overexpressing the DbRII exhibited a higher susceptibility to chemical carcinogenesis (Amendt et al., 1998; Go et al., 1999) . In addition to TGFb signaling, overexpression of BMP-4 in transgenic epidermis also inhibits tumorigenesis in a skin chemical carcinogenesis model QUOTE (Blessing et al., 1995) . As the major signaling mediators of TGFb superfamily, Smads may be actively involved in maintaining skin homeostasis, and in tumor suppression during skin carcinogenesis. In addition, Smads by themselves have been suggested to be tumor suppressors. Smad2, -4 and -5 are located at chromosomal positions that harbor tumor suppressor genes and are often deleted in malignant tumors (Barrett et al., 1996; Devereux et al., 1997; Hejlik et al., 1997; Hoque et al., 1997; Kong et al., 1997; Rozenblum et al., 1997; Schutte et al., 1996; Takagi et al., 1996; Uchida et al., 1996; Ueda et al., 1997; Zavadil et al., 1997) . Point mutations of Smad2 and -4 have also been found in cancers (Devereux et al., 1997; Hahn et al., 1996; Jonson et al., 1999; Miyaki et al., 1999; Moskaluk et al., 1997) . Smad3 7/7 mice generated by Zhu et al. (1998) develop colon cancer.
Because of the skin being a major target of the TGFb superfamily, the relevance of skin carcinogenesis to carcinogenesis in other epithelial tissues and the accessibility of the skin, the epidermis is an ideal tissue to study the role of TGFb signaling under normal and carcinogenic conditions. Another advantage of utilizing the skin is that the skin chemical carcinogenesis model is one of the most widely utilized and reliable models for studying the multistage process of cancer. This system identi®ed carcinogenesis as distinct stages of initiation, promotion, and malignant conversion (DiGiovanni, 1992) . Initiation is induced by topical application of a sub-carcinogenic dose of a particular carcinogen, e.g., dimethylbenzanthracene (DMBA). Following initiation, a tumor promoter, e.g., 12-Otetradecanoylphorbol-13-acetate (TPA), is applied to elicit benign papillomas. After promotion, papillomas can persist, regress, or convert to malignancy (DiGiovanni, 1992) .
In the present study, we examined Smad expression at both the RNA and protein levels in normal keratinocytes and chemically-induced skin tumors. In addition, we screened mutations for the Smad2 and -4 genes from these tumors. We provide evidence that Smad1 through -5 are expressed at high levels in the epidermis and may transduce TGFb signaling in normal keratinocytes. However, loss of these Smads at the post-transcriptional level, as well as an increase in Smad7 at the transcriptional level, may contribute to the loss of TGFb-induced growth inhibition, resulting in tumor progression.
Results

Expression of Smad transcripts in cultured keratinocytes, the epidermis and chemically-induced skin tumors
To determine which Smad isoforms are expressed in the epidermis, initially, reverse transcription-polymerase chain reaction (RT ± PCR) was used to detect transcripts of Smad1 through -7. Transcripts of Smad1 through -5 were detected in mouse epidermis. These RT ± PCR products, together with RT ± PCR fragments of Smad6 and -7 from the heart, were subcloned and used as riboprobes in RNase protection assays (RPA) to further quantitate expression of the Smad isoforms. RPA con®rmed that Smad1 through -5 were expressed in cultured primary keratinocytes, the epidermis and chemically induced skin tumors (Figure 1a, b) . Among these Smad transcripts, Smad1 and -5 were expressed at a similar and the lowest level. Smad2 and -3 were expressed at a similar level, which was threefold higher than Smad1 and -5 (Figure 1a,b) . Smad4 was expressed at the highest level, which was ®vefold higher than Smad1 and -5 (Figure 1a,b) . This pattern of Smad expression was virtually the same between proliferative and dierentiated keratinocytes ( Figure  1a) , and between neonatal and adult epidermis ( Figure  1b) . Treatment of both proliferative and dierentiated keratinocytes with 1 ng/ml TGFb1 for 24 h did not signi®cantly alter mRNA levels of Smad1 through -5 ( Figure 1a ). In addition, although it has been documented that the TGFb transcripts are elevated in chemically-induced papillomas and SCC (Akhurst et al., 1988; Fowlis et al., 1992; Krieg et al., 1991; Patamalai et al., 1994; Rundhaug et al., 1997; Sherman et al., 1993) , we did not observe signi®cant changes in the level of Smad1 through ®ve transcripts in papillomas or SCC (Figure 1b) . Transcripts of Smad6 were undetectable in all samples examined (not shown). Transcripts of Smad7 were undetectable in proliferative and dierentiated keratinocytes ( Figure  1c ) and barely detectable in normal epidermis ( Figure  1d ). However, RT ± PCR for Smad7 yielded a faint, positive band in TGFb1-treated proliferative and dierentiated keratinocytes (Figure 1c ). This band was con®rmed by DNA sequencing to be a fragment of Smad7 cDNA. Smad7 was also up-regulated by threefold in papillomas and SCC, in comparison with normal epidermis (P50.001, Figure 1d ). These data indicate that Smad1 through -5 are not transcriptionally regulated in response to TGFb signaling. Since TGFb1 has been documented to be up-regulated in papillomas and SCC (Akhurst et al., 1988; Fowlis et al., 1992; Go et al., 1999; Rundhaug et al., 1997) , the data suggest that Smad7 expression is transcriptionally up-regulated by TGFb1 in normal keratinocytes and chemically-induced skin tumors.
Localization of Smads in the skin
To localize Smad transcripts in the skin, in situ hybridization was performed on frozen sections of neonatal mouse skin, utilizing digoxigenin-11-UTP labeled riboprobes speci®c for mouse Smad1 through -7 mRNA. Similar to the expression patterns of Smad transcripts detected in cultured keratinocytes ( Figure  1a ), Smad1 through -5 transcripts were detected throughout all layers of the epidermis, including both the basal proliferative keratinocytes and suprabasal dierentiated keratinocytes (Figure 2 ), whereas Smad6 and -7 were barely detectable in the epidermis (not shown). In addition, Smad1, 4 and 5 were also detected in hair follicles with intensities similar to those in the Loss of Smads in skin carcinogenesis W He et al epidermis ( Figure 2 ). In contrast, expression levels of Smad2 and -3 in hair follicles were much weaker than the epidermis (Figure 2 ). Expression levels of all these Smad transcripts in the dermis were signi®cantly lower than the epidermis (Figure 2 ). To localize Smad proteins in the skin, immunohistochemical staining of Smads was performed on mouse skin. In contrast to their constant expression patterns at the transcriptional level, Smad2 through -5 proteins showed stronger staining in suprabasal layers than the basal layer of the epidermis, whereas Smad1 stained uniformly in the epidermis (Figure 3 ). The subcellular localization of Smad2 through -5 was similar: the staining was either in the cytoplasm or/and in the nucleus (Figure 3 ). Smad1 stained primarily in the cytoplasm of the epidermis, hair follicles, and some dermal ®broblasts (Figure 3 ). Although both Smad1 and -5 have been suggested to mediate BMP signaling, the staining pattern of Smad5 in the skin was dierent from Smad1 ( Figure 3 ). Smad5 stained strongly above the granular layers of the epidermis, hair follicles and dermal ®broblasts, with many cells stained positive in the nucleus (Figure 3 ). Smad2 and -3 showed a similar staining pattern: a similar intensity in the suprabasal layers of the epidermis and lower levels in the basal layer and hair follicles ( Figure 3 ). In addition, the number of Smad2 or Smad3 positive cells in the dermis was less than Smad4 or Smad5 positive cells (Figure 3 ). Among these Smad isoforms, Smad4 stained the strongest in the epidermis and hair follicles, with many dermal ®broblasts stained positive for Smad4 ( Figure  3 ). 
TGFb1 induces nuclear translocation of Smad2, -3 and -4 in cultured keratinocytes
To determine whether Smads respond to TGFb signaling in the epidermis at the protein level, expression of Smad proteins was examined in cultured keratinocytes by immuno¯uorescence. Smad2 and -3 were individually detected with a similar intensity (not shown), or with an antibody that recognizes both Smad2 and -3 (Figure 4 ). Under proliferation condi- Figure 2 In situ hybridization of Smad1, -2, -3, -4 and -5 on frozen sections of neonatal mouse skin. The arrows in Smad2 and -3 panels point out hair follicles. Note that staining for Smad2 and -3 in hair follicles was less than that in the epidermis. The bar in Smad1 panel represents 25 mm for all panels
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W He et al tions, localization of Smad2, -3, -4 was variable: some keratinocytes exhibited stronger staining in either the nucleus or the cytoplasm, some showed equal staining in both the cytoplasm and the nucleus (Figure 4) . In most cells, staining of Smad2 and -3 was greater in the cytoplasm, with the greatest staining in the perinuclear area ( Figure 4a , upper panels). Staining of Smad4 was greater in the perinuclear region ( Figure 4b , upper panels). To con®rm that these cultured keratinocytes were truly in a non-dierentiated state, they were counter-stained with an antibody against keratin 14 (K14) which is expressed in proliferative keratinocytes (Roop et al., 1987) , and an antibody against keratin 1 (K1) which is an early dierentiation marker (Roop et Immuno¯urorescence of Smad2, -3 and -4 in cultured keratinocytes. Keratinocytes in 0.05 mM Ca 2+ culture medium stained for Smad2/Smad3 (a, red) or Smad4 (b, red), but did not stain for K1 (green), indicating the non-dierentiated state. Nuclear translocation of Smads (a, b) induced by TGFb1 treatment is more obvious when counterstained with K14 (green). Keratinocytes in 0.35 mM Ca 2+ culture medium (c) stained for Smad2/Smad3 or Smad4 (red) in both the cytoplasm and the nucleus, and underwent nuclear translocation upon TGFb1 treatment (lower panels). The counterstain is K1 (green), indicating the dierentiated state of these keratinocytes. Bar represents 50 mm (Figure 4c ), whereas Smad4 staining was relatively uniform in both the cytoplasm and the nucleus (Figure 4c ). To determine whether Smad proteins respond dierently to TGFb signaling in dierentiated vs proliferative keratinocytes, cultured keratinocytes were treated with 1 ng/ml of exogenous TGFb1. Twenty-four hours after TGFb1 treatment, TGFb1 completely inhibits keratinocyte proliferation (Wang et al., 1997) . At this time point, Smad2, -3 and -4 all showed nuclear localization in either proliferative or dierentiated keratinocytes (Figure 3a ,b,c, lower panels).
BrdU labeled keratinoytes show cytoplasmic staining of Smad2, -3 and -4
To determine whether TGFb1-induced nuclear translocation of Smad2, -3 and -4 correlates with the growth inhibitory eect of TGFb1, cultured keratinocytes were labeled with BrdU and stained for Smad2, -3 and -4. In normal proliferative keratinocytes, BrdU positive cells showed cytoplasmic staining of Smad2, -3 and -4 ( Figure 5 ). Six hours after 1 ng/ml TGFb1 treatment, keratinocyte proliferation was signi®cantly reduced (but not completely blocked as it is at the 24 h time point). This is evident by a signi®cant reduction of BrdU positive cells (Figure 5 ). At this stage, many keratinocytes showed nuclear translocation of Smad2, -3 and -4. Notably, none of the cells with nuclear translocation of Smads stained positive for BrdU, and sporadic BrdU labeled cells were found among cells that retained cytoplasmic staining of Smads ( Figure 5 ). This result suggests that nuclear translocation of Smads may be required to mediate TGFb1-induced growth arrest.
Chemically-induced skin tumors did not exhibit mutation in Smad2 and -4
Mutations in Smad2 and -4 genes were screened in chemically-induced skin tumors. In total, 16 papillomas and 24 SCC were analysed. No mutations were found in Smad2 and -4 in these tumor samples (data not shown).
Loss of Smad proteins in chemically-induced skin tumors
Since we did not detect either the loss of Smad transcripts or mutations in Smad genes in chemicallyinduced skin tumors, we further examined proteins of Smad isoforms. At the early stage of skin carcinogenesis, all these Smad isoforms were detected in a majority of papillomas, at levels comparable to normal epidermis ( Figure 6 ). In contrast, staining of R-Smads, Smad1, -2, -3 and -5, was signi®cantly reduced in all of SCC examined (Figure 7) . In 14 SCC examined, 11 SCC showed an undetectable level of Smad3 protein, and 7 SCC were negative for Smad1, -2 or -5. Although Smad4 was not completely lost in most SCC, it showed a signi®cant reduction in intensity (Figure 7) . When tumors further progressed to poorly dierentiated spindle cell carcinomas (SPCC), a complete loss of all these Smad isoforms was observed (data not shown).
Discussion
Smads comprise a novel family of signaling mediators downstream of TGFb receptors. They transmit signals directly from the cell surface to the nucleus. Although the biochemical characterization of these Smads has brought remarkable achievements in the elucidation of the intracellular signaling pathway of TGFb, little is known about their regulation and functions in the skin, a major target tissue for TGFb. In the present study, we examined expression of Smads in mouse epidermis and in chemically-induced skin tumors.
The staining patterns of Smads suggest that they transduce TGFb signaling in both proliferative and differentiated keratinocytes
In normal keratinocytes, transcripts of Smad1 through -5 are stably expressed regardless of changes in TGFb signaling, stage of development (neonates vs adults), and state of dierentiation. However, Smad proteins are expressed at higher levels in dierentiated keratinocytes, and are suggested to mediate TGFb signaling in these keratinocytes. First, in normal epidermis, Smad2, -3, -4 and -5 proteins were detected at higher levels in suprabasal layers. Secondly, in cultured keratinocytes that underwent terminal dierentiation, Smad2, -3 and -4 exhibited nuclear translocation in response to exogenous TGFb1 treatment (Figure 4c ). Considering that TGFb plays an important role in growth inhibition in keratinocytes, it is possible that TGFb signaling in suprabasal layers is important to keep these cells committed to terminal dierentiation, and to prevent them from regaining proliferative potential. Furthermore, TGFb may directly regulate epidermal dierentiation via interaction with Smads. As such, Smads have been shown to transactivate TGFb responsive genes related to epidermal dierentiation, including p21 (WAF-1) (Li et al., 1998) and AP-1 family members (Jonk et al., 1998; Wong et al., 1999; Zhang et al., 1998) . In addition, Smads may aect epidermal dierentiation via TGFb-independent pathways. Potential candidates for these TGFb-independent genes include calmodulin, NF-kB, and the vitamin D receptor, all of which have been shown to play an important role in epidermal dierentiation (Bikle and Pillai, 1988; Hu et al., 1999; Li et al., 1999; Ma et al., 1997; Roop et al., 1987; Rougui et al., 1996; Takeda et al., 1999) , and to interact directly with Smads (Kon et al., 1999; Yanagisawa et al., 1999; Zimmerman et al., 1998) . Therefore, it will be worthwhile to further determine the exact role of Smads in epidermal dierentiation in the future.
The role of TGFb in growth inhibition in proliferative keratinocytes has been well documented. Although Smad proteins were less abundant in the basal layer than suprabasal layers of the epidermis, they are suggested to mediate TGFb-induced growth arrest. This is evident by nuclear translocation of Smad2, -3, and -4 after treatment with TGFb1 in cultured proliferative keratinocytes. Furthermore, BrdU labeling occurred in keratinocytes with a cytoplasmic staining pattern of Smad2, -3 and -4, and the reduced BrdU labeling induced by TGFb1 treatment coincided with the nuclear translocation of Smad2, -3 and -4 ( Figure 5 ).
The staining patterns of Smads in hair follicles vary among dierent isoforms. Transcripts for Smad1, -4, and -5 were strongly expressed hair follicles, whereas transcripts for Smad2 and -3 were expressed at lower levels in hair follicles than in the epidermis. Expression of Smad proteins in hair follicles correlated with their Although both Smad1 and -5 stained positive in hair follicles, Smad1 stained primarily in the cytoplasm, whereas Smad5 primarily stained in the nucleus. These variations suggest that dierent Smad isoforms may aect hair follicle dierently during hair formation and homeostasis. Hair follicles harbor epidermal stem cells that determine epidermal proliferation, dierentiation and regeneration. Therefore, if some of these Smads have eects on hair follicles, they may potentially aect epidermal development, wound-healing and carcinogenesis.
Loss of Smad-mediated signaling may be involved in tumor progression during skin carcinogenesis
Since Smads have been suggested to inhibit epidermal proliferation and may also be involved in epidermal dierentiation, loss of these functions would ultimately promote tumorigenesis in the skin. Although our current study did not detect mutations in Smad2 and -4 genes of chemically induced skin tumors, malignant SCC exhibited decreased protein levels of these gene products. Therefore, loss of Smad signaling in skin carcinogenesis may primarily occur at the protein level. Among R-Smads, Smad3 showed the highest rate for a complete loss in SCC. Although mutations in the Smad3 gene have not been identi®ed, in vitro studies have suggested that loss of Smad3 abolishes TGFbinduced growth inhibition (Abdollah et al., 1997) . Additionally, Smad3 knockout mice show spontaneous colon cancer (Zhu et al., 1998) . Therefore, Smad3 may normally play a tumor suppressive role in skin carcinogenesis, and loss of Smad3 protein in skin tumors may contribute to malignant progression. In addition to the decreased protein levels of TGFbsignaling Smads, BMP-signaling Smads were also reduced in SCC. Although Smad5 deletion occurs at a less frequency in human cancers than Smad2 and -4 (Zavadil et al., 1997) , and no mutations have been identi®ed in Smad1 and -5 genes, our current study shows that loss of Smad1 and -5 in malignancies can occur at the protein level. Since BMP has been Figure 7 Immunohistochemical staining of Smad1 through -5 in DMBA/TPA-induced SCC. Note a complete loss of Smad1, -2, -3 and -5 in SCC, although the adjacent epidermis and hair follicles stained strongly for these Smads (shown in Smad2 staining, the upper-right corner). In comparison to Smad4 staining in the adjacent papilloma (upper-right corner), SCC showed a reduced staining of Smad4. The bar in Smad1 panel represents 150 mm for all panels suggested to play a tumor suppressive role in skin chemical carcinogenesis (Blessing et al., 1995) , loss of Smad1 and -5 may result in the loss of the tumor suppressive eect of BMP. In addition, Smad5 may also mediate TGFb signaling, suggested by the phenotype of Smad5 knockout mice, which is reminiscent of BMP-4, TGFb1 and TGFbRII knockout mice (Chang et al., 1999) . Therefore, loss of Smad5 may also result in decreased TGFb signaling in skin carcinogenesis.
The mechanisms by which the tumor cells lose proteins of R-Smads and Co-Smad are unclear. Since loss of Smads occurred at least 20 weeks after the last TPA application, it is unlikely that TPA or DMBA application directly results in decreased Smads. Therefore, loss of Smad proteins most likely occurs as the result of subsequent genetic changes involved in progression of chemically induced tumors. Increased protease activity in tumor cells may contribute to the degradation of these Smads. For instance, the ubiquitin-speci®c proteasome pathway has recently been identi®ed to be responsible for Smad2 degradation (Heldin and ten Dijke, 1999; Lo et al., 1999) . In addition to the decrease in R-Smads and Co-Smad in SCC, the anti-Smad, Smad7 is up-regulated transcriptionally in tumor cells. Transcriptional up-regulation of Smad7 by TGFb1 has been observed in other tissues (Nakao et al., 1997) . Since Smad7 has an antagonistic eect on TGFb signaling, the induction of Smad7 mRNA by TGFb suggests that Smad7 may participate in a negative feedback loop to control TGFb responses in normal epidermis. During skin carcinogenesis, Smad7 mRNA was also elevated in both papillomas and SCC. This may also be the result of increased expression of TGFb during skin carcinogenesis (Akhurst et al., 1988; Fowlis et al., 1992; Go et al., 1999; Rundhaug et al., 1997) . However, at this stage, particularly in SCC, R-Smads and Co-Smad were decreased. Thus, up-regulation of Smad7 would further contribute to the loss of TGFb-induced growth inhibition in these tumor cells.
It has been documented that TGFb1 is overexpressed in both benign papillomas and malignant SCC in skin chemical carcinogenesis models (Akhurst et al., 1988; Fowlis et al., 1992; Go et al., 1999; Rundhaug et al., 1997) . However, it is unclear whether overexpression of TGFb1 truly enhances TGFb signaling in skin carcinogenesis. Our current study shows that although the TGFb1 ligand is still upregulated in SCC, R-Smads and Co-Smad are decreased, and Smad7 is elevated in SCC. Thus, it is likely that overexpression of TGFb1 at earlier stages of carcinogenesis provides a growth inhibitory eect on tumor cells via Smad signaling. However, with the decrease in R-Smads and Co-Smad, and elevation of Smad7 in SCC, overexpression of TGFb1 would no longer be able to inhibit tumor growth. Therefore, loss of Smad signaling in tumor cells may contribute to the role switch of TGFb, i.e., from being a tumor suppressor to a tumor promoter. At this stage, TGFb1 overexpression no longer inhibits tumor growth partially (if not all) due to decreased Smad signaling in tumor cells. Instead, TGFb will have a paracrine eect on remodeling tumor stroma (Cui et al., 1996) and increasing angiogenesis (Go et al., 1999; to promote tumor progression.
In summary, our current study documents that RSmads and Co-Smad are expressed in the epidermis at high levels, and mediate TGFb signaling in both proliferative and dierentiated keratinocytes. However, during skin carcinogenesis, these Smads are lost in malignant carcinomas and an anti-Smad is upregulated. The changes of Smads in SCC may result in tumor cells escaping from TGFb/BMP-induced growth inhibition and progressing to malignancy. This hypothesis can be further tested in the future by generating transgenic/knockout mouse models in which Smads are either overexpressed or deleted in the epidermis, and examining spontaneous and chemically-induced skin tumors in these models. The loss of multiple R-Smad proteins and up-regulation of the anti-Smad in SCC also suggest that individual Smads may have non-overlapping functions in tumor suppression, and loss of one isoform may not be sucient for malignant conversion. Therefore, these data warrant future studies to explore the functions and mechanisms of each Smad in the epidermis under normal and carcinogenic conditions.
Materials and methods
Primary keratinocyte culture
Primary keratinocytes were prepared from newborn mouse skin as described (Wang et al., 1997) , and plated on either 60 mm culture dishes or chamber slides (Lab-Tak) fed by 50% ®broblast conditioned medium (CM) supplemented with 2 ng/ml EGF and 0.05 mM Ca
2+
. Twenty-four hours after plating, the cells were fed with 50% CM with either 0.05 mM Ca 2+ to maintain the proliferative state or 0.35 mM Ca 2+ to induce keratinocyte dierentiation (Roop et al., 1987) . Keratinocytes were cultured for 48 h before human TGFb1 (1 ng/ml, Oncogene Science) was added to the media. Twenty-four hours later, cells were washed with PBS three times, and harvested for RNA extraction or ®xed for immuno¯uorescence. For bromodeoxyuridine (BrdU) incorporation analysis, BrdU (200 mg/ml) was added to media 6 h after TGFb1 treatment. Cells were washed and ®xed 1 h later.
Chemical carcinogenesis protocol
A chemical carcinogenesis protocol was applied to 10-weekold ICR mice, as previously described (Go et al., 1999) . Brie¯y, 50 mg of DMBA was topically applied to the back skin of a mouse. One week after DMBA initiation, mice were topically treated with 5 mg of TPA, once a week for 20 weeks. Tumor types biopsied from these mice were determined by histology following the criterion described by (Aldaz et al., 1987) . Typically, tumors were biopsied at 20 ± 30 weeks after DMBA initiation for papillomas, and 40 ± 50 weeks for squamous cell carcinomas (SCC).
RT ± PCR and RPA for Smad mRNA expression
Total RNA from cultured keratinocytes, the epidermis and tumor was isolated using RNAzol B (Tel-Test, Inc.) as previously described . To determine which Smad transcripts are expressed in the epidermis, RT ± PCR and RPA were performed. In RT ± PCR assays, RNA was reverse transcribed using MMLV reverse transcriptase (Promega) and pdN6 random primers (Boehringer Mannheim). The resultant cDNA was ampli®ed by PCR using the primers speci®c for mouse Smad isoforms and b-actin. The primers are: Smad1: 5'-CTCACATGCCACTGAACGCC-3'; 5'-TCCGCATACACCTCTCCTCC-3'. Smad2: 5'-GGAAA-GGGTTGCCACATGTT-3'; 5'-AGAATCTCCGTGTGCC-GAGG-3'. Smad3: 5'-GTTGGACGAGCTGGAGAAGG-3'; 5'-TGCTGTGGTTCATCTGGTGG-3'. Smad4: 5'-ACGGC-CATCTTCAGCACCAC-3'; 5'-AGAATGCACAATCGCC-GGAG-3'. Smad5: 5'-TTTGCAGAGCCATCACGAGC-3'; 5'-TTTCCAATATGCCGCCTAGT-3'. Smad6: 5'-TGCCT-GAGAGTGACTGCGAG-3'; 5'-TCAGGAGGAGACAGC-CGAGA-3'. Smad7: 5'-GCTCACGCACTCGGTGCTCA-3'; 5'-CCAGGCTCCAGAAGAAGTTG-3'. b-Actin: 5'-CTAC-AATGAGCTGCGTGTGG-3'; 5'-TAGCTCTTCTCCAGG-GAGGA-3'.
The RT ± PCR fragments of Smad1 ± 5 from epidermal RNA, and Smad6 and -7 from heart RNA, were subcloned into the pGem-T vector (Promega), sequenced, and used as riboprobe templates in RPA. RPA was performed using an RPA II kit (Ambion) and 32 P-labeled riboprobes speci®c for the above Smad isoforms. To normalize each RNA sample for dierences in loading, a 32 P-cyclophilin riboprobe was included in each assay. The intensity of the protected bands was determined by densitometeric scanning of X-ray ®lms. Quantitation of each Smad band was determined by the intensity of Smad isoforms vs that of cyclophilin.
In situ hybridization for localization of Smad mRNA
In situ hybridization was performed as described previously (Nadeau et al., 1997) , with minor modi®cations. Brie¯y, antisense and sense riboprobes speci®c for individual Smads were labeled with digoxigenin-11-UTP, utilizing the same templates used in PRA described above. Neonatal mouse skin was frozen in OCT (Tissue-Tek) and sectioned to 10 mm on ProbeOn Plus slides (Fisher). The sections were ®xed in 4% paraformaldehyde in PBS (pH 7.4) for 20 min, treated with 0.2 M HCl for 15 min, and digested with 2 mg/ml of proteinase K in 0.1 M Tris-HCl (pH 8.0) at 378C for 20 min. The sections were then treated with 0.1 M glycine for 5 min, re-®xed with 4% paraformaldehyde for 10 min, and acetylated in 0.25% acetic anhydride/0.1 M triethanolamine (pH 8.0) for 2610 min. The sections were prehybridized in hybridization buer (56SSC, 16Denhardt's solution, 50% formamide, 1 mg/ml yeast tRNA, 0.1%CHAPS, 0.1%Tween 20, 100 mg/ml heparin and 5 mM EDTA) for 3*5 h at 428C. Hybridization was carried out overnight at 428C in a fresh hybridization buer containing 1 mg/ml of an antisense or a sense probe. After hybridization, the sections were washed twice in 26SSC, and treated with RNase A at 378C for 30 min. The slides were then washed with 26, 16 and 0.56 SSC at 428C, and PBS at room temperature. Immunological detection of the hybridized probes was performed with an anti-digoxigenin antibody conjugated with alkaline phosphatase (1 : 2000), and developed with the nitroblue tetrazolium chloride (NBT)/5-bromo-4-chloro-3-indolyl-phosphate (BCIP) color substrates (Roche Diagnostics GmbH).
Immunohistochemistry staining of Smads in the epidermis and tumors
Skins from neonatal and adult mice and tumors were ®xed in 10% formalin-PBS (pH 7.4), embedded in paran and sectioned to 6 mm on VWR slides (VWR Scienti®c). The sections were deparanized in xylenes and rehydrated through an ethanol series. The sections were treated with 10 mM sodium citrate (pH 6.0) at 958C for 10 min, cooled to room temperature, and treated with 2N HCl at room temperature for 30 min. Endogenous peroxidase activity was quenched by incubating sections in 0.6% H 2 O 2 in H 2 O at room temperature for 10 min. The sections were blocked with 5% normal donkey serum at room temperature for 1 h, followed by incubation with a Smad antibody (4 mg/ml, diluted in 1%BSA-TBS) at room temperature for 2 h. The following goat anti-Smad antibodies were used: Smad1 (T-20, Santa Cruz); Smad2 (S-20, Santa Cruz); Smad3 (I-20, Santa Cruz); Smad4 (C-20, Santa Cruz); Smad5 (D20, Santa Cruz);. Sections were then washed with PBS and a biotinylated donkey anti-goat IgG (4 mg/ml, Santa Cruz) was applied for 1 h at room temperature. The immune complex was detected by the avidin-biotin-peroxidase complex using Vectastain kits (Vector Lab, CA). Immune complexes were visualized with diaminobenzidine and counterstained with hematoxylin.
Immunofluorescence for Smads staining in cultured keratinocytes
Cells were ®xed with cold methanol for 10 min, and treated with 2 N HCl for 30 min at room temperature. Fixed keratinocytes were blocked with 5% donkey serum in 1% BSA-TBS at room temperature for 1 h. For double-labeling Smads and keratins, the Smad antibody (2 mg/ml) and the rabbit anti K14 or K1 antibody (1 : 500), diluted in 1%BSA-TBS (w/v), were applied to the sections and incubated at room temperature for 2 h. The Smad antibodies used were: Smad2/3 (E-20, Santa Cruz) that recognizes both Smad2, -3, and -4 (C-20, Santa Cruz). For double-labeling of BrdU and Smads, FITC-conjugated mouse monoclonal anti-BrdU (Becton-Dickenson) and the goat anti-Smad2/3 or Smad4 (4 mg/ml in 1% BSA-TBS) were applied to the sections and incubated at room temperature for overnight. Sections were then washed as above and biotinylated donkey anti-goat IgG was applied (4 mg/ml, Santa Cruz) for 30 min at room temperature. Cells were washed again and a 1 : 400 dilution Streptavidin-Texas Red (Gibco) and a 1 : 40 dilution of FITCconjugated, anti-rabbit IgG (Dako) (for rabbit anti-K1 or K14) was applied for 30 min at room temperature. The slides were then washed, air dried, cover-slipped and photographed.
Analysis of mutations in Smad2 and -4 genes
Tumor DNA was isolated as previously described (Go et al., 1999) . PCR was applied to tumor DNA to amplify exon 2 to exon 11 of Smad2 and -4. The PCR products were then puri®ed through a PCR puri®cation kit (Qiagen), and analysed by automated sequencing.
